Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$69.00 USD

69.00
3,405,133

-0.70 (-1.00%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Instruments

Zacks News

Here's Why Investors Should Retain Labcorp (LH) Stock for Now

Investors are increasingly optimistic about Labcorp (LH) due to development in targeted high-growth areas.

Orthofix (OFIX) Q3 Earnings Top Estimates, 2023 Sales View Cut

Orthofix (OFIX) saw very strong growth across multiple business segments and product lines in Q3.

Labcorp (LH) Closes the Legacy Health Asset Acquisition Deal

Labcorp (LH) finalizes the comprehensive laboratory relationship with Legacy Health.

Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?

Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.

EssilorLuxottica (ESLOY), Moncler Ink Luxury Eyewear Deal

The first Moncler Lunettes collection produced with EssilorLuxottica (ESLOY) is called Fall-Winter 2024.

Here's Why You Should Retain Edward Lifesciences (EW) Stock Now

Investors remain optimistic about Edward Lifesciences (EW) due to Surgical's differentiated portfolio and TMTT franchise.

Quest Diagnostics' (DGX) New Pact to Advance Cancer Screening

Quest Diagnostics' (DGX) latest partnership will increase the likelihood that Americans will eventually have an easy, reliable and accessible way to check for colorectal cancer.

Abbott (ABT) Benefits From Innovation Amid FX Headwinds

Abbott's (ABT) mAbxience collaboration is likely to help introduce cutting-edge medicines in the areas of oncology, women's health and respiratory diseases.

Teleflex (TFX) Enrolls First Patient in ACCESS-MANTA Registry

Teleflex's (TFX) ACCESS-MANTA Registry is likely to examine the contemporary on-label use of the MANTA VCD.

Medtronic (MDT) Q2 Earnings Beat Estimates, 2024 View Up

Medtronic (MDT) Q2 results reflect broad strength across businesses and geographies, benefiting from durable fundamentals.

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

Investors are optimistic about Myriad Genetics (MYGN) on recent partnerships and growth in testing volumes.

Zimmer Biomet's (ZBH) Knee Sales Robust, Macro Woes Hurt

Zimmer Biomet (ZBH) is working to strengthen its foothold in emerging markets that provide long-term opportunities for growth.

Boston Scientific (BSX) Closes the Relievant Medsystems Buyout

Boston Scientific (BSX) expands the neuromodulation portfolio with the acquisition of Relievant Medsystems.

Here's Why Investors Should Retain STERIS (STE) Stock for Now

STERIS' (STE) Healthcare segment continues to benefit from procedure volume recovery.

DexCom (DXCM) is an Incredible Growth Stock: 3 Reasons Why

DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.

National Vision's (EYE) Market Expansion Aids, Inflation Ails

National Vision (EYE) is expanding sales by the continued rollout of its remote medicine technology.

Myriad Genetics (MYGN) Expands Pharma Services With New Pact

Myriad Genetics (MYGN) will market the Personalis ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners with a new collaboration.

Medtronic's (MDT) Symplicity Spyral RDN System Gets FDA Boost

Medtronic (MDT) receives the FDA approval for Symplicity blood pressure procedure for the treatment of hypertension.

Paragon 28 (FNA) BEAST Cortical Fibers Launch Boosts Biologics

Paragon 28's (FNA) BEAST Cortical Fibers' advanced processing capability ensures the preservation of native bone morphogenic proteins and other growth factors crucial for bone formation.

Zacks.com featured highlights include DexCom, Arthur J. Gallagher, Limbach and The Hartford Financial Services

DexCom, Arthur J. Gallagher, Limbach and The Hartford Financial Services are part of the Zacks Screen of the Week article.

Nemaura (NMRD) to Expand in UK With Metabolic Health Program

The latest program leverages Nemaura's (NMRD) world-first daily wear non-invasive CGM technology, providing individuals with real-time insights into their body's glucose dynamics.

What's in the Cards for Medtronic (MDT) in Q2 Earnings?

Strength in all four businesses is likely to drive Medtronic's (MDT) fiscal second-quarter performance.

Neogen's (NEOG) Innovation Aids, Currency Headwind Stays

Neogen (NEOG) is progressing well in terms of picking the right growth markets and gaining a bigger share of those markets.

Reasons to Add DexCom (DXCM) Stock to Your Portfolio Now

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Charles River (CRL) Widens CliniPrime GMP Suite With New Launch

Charles River (CRL) brings CliniPrime Cryopreserved Leukopaks for cell therapy development and manufacturing.